Navigation Links
Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement
Date:6/30/2009

LAKE FOREST, Ill., June 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced agreements with MedAssets on intravenous (I.V.) solutions and gravity I.V. equipment, and a renewal of its agreement for infusion devices. The five-year MedAssets agreements are effective as of June 1, 2009, for I.V. solutions and equipment, and July 1, 2009, for infusion devices. These new agreements represent a first for Hospira from a contract award position on I.V. solutions and gravity I.V. equipment.

"MedAssets shares Hospira's commitment to improving patient and healthcare safety, as well as finding ways to reduce the high costs of healthcare," said Pete Baker, vice president and general manager, Commercial Service Operations, Hospira. "We look forward to continuing our work with MedAssets' member healthcare institutions to drive these goals."

The agreements, all of which run through June 30, 2014, are multi-source awards. They include Hospira's general-purpose medication management technologies, such as the Plum A+(R) device; the next-generation Symbiq(R) infusion system with Hospira MedNet(R) safety software; and pain management pumps, such as the LifeCare PCA(R) device with Hospira MedNet(R) safety software, and GemStar(R) ambulatory devices. These products play a critical role in improving patient safety as well as enhancing quality of care and clinician workflow. Also covered within the agreements is access to contracts for Hospira's I.V. solutions, including the company's environmentally preferable VisIV(R) container, and the IV solutions' associated equipment portfolio.

"We are pleased to expand our relationship with Hospira," said Mark Miriani, president of MedAssets Supply Chain Systems. "Adding Hospira's full line of I.V. solutions and gravity I.V. equipment to our existing portfolio provides additional options for our members as part of our flexible, customer-driven approach to reducing supply expenses for our members."

About MedAssets

MedAssets (Nasdaq: MDAS) partners with healthcare providers to improve their financial strength by implementing spend management and revenue cycle solutions that help control cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency. MedAssets serves more than 125 health systems, 3,300 hospitals and 30,000 non-acute care healthcare providers. For more information, visit www.medassets.com.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hospira Receives Favorable Court Decision on Eloxatin(R)
2. Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies
3. Hospira Names Brian Meadows Supply Chain Chief
4. Hospira Supports Newly Introduced Biogenerics Legislation
5. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
6. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
7. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
8. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
9. Hospira Expands Board of Directors
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Biogenerics Will Save Billions, Says Hospira CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):